fluoxetine has been researched along with Amblyopia in 4 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Amblyopia: A nonspecific term referring to impaired vision. Major subcategories include stimulus deprivation-induced amblyopia and toxic amblyopia. Stimulus deprivation-induced amblyopia is a developmental disorder of the visual cortex. A discrepancy between visual information received by the visual cortex from each eye results in abnormal cortical development. STRABISMUS and REFRACTIVE ERRORS may cause this condition. Toxic amblyopia is a disorder of the OPTIC NERVE which is associated with ALCOHOLISM, tobacco SMOKING, and other toxins and as an adverse effect of the use of some medications.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amblyopia is a common visual disorder that is treatable in childhood." | 6.87 | Fluoxetine does not enhance the effect of perceptual learning on visual function in adults with amblyopia. ( Booms, S; Castrén, E; Huttunen, HJ; Karvonen, E; Latvala, ML; Liinamaa, J; Lindberg, L; Palva, JM; Palva, S; Saarela, V; Uusitalo, H, 2018) |
| "In this double-blinded, randomized, controlled trial (IRCT2016052428046N1; registered retrospectively), 40 eligible participants with anisometropic or mixed amblyopia were randomly assigned to either fluoxetine or placebo groups." | 5.30 | Oral fluoxetine in the management of amblyopic patients aged between 10 and 40 years old: a randomized clinical trial. ( Khalili, MR; Nowroozzadeh, MH; Rastegar, K; Sharif, MH; Talebnejad, MR, 2019) |
| "Amblyopia is a common visual disorder that is treatable in childhood." | 2.87 | Fluoxetine does not enhance the effect of perceptual learning on visual function in adults with amblyopia. ( Booms, S; Castrén, E; Huttunen, HJ; Karvonen, E; Latvala, ML; Liinamaa, J; Lindberg, L; Palva, JM; Palva, S; Saarela, V; Uusitalo, H, 2018) |
| "Amblyopia is a developmental brain disorder in which vision is lost due to asymmetric or inadequate visual stimulation early in life." | 2.53 | Medical Therapies of Amblyopia: Translational Research to Expand Our Treatment Armamentarium. ( Gore, C; Wu, C, 2016) |
| " We found that chronic administration of fluoxetine reinstates ocular dominance plasticity in adulthood and promotes the recovery of visual functions in adult amblyopic animals, as tested electrophysiologically and behaviorally." | 1.35 | The antidepressant fluoxetine restores plasticity in the adult visual cortex. ( Baroncelli, L; Castrén, E; De Pasquale, R; Maffei, L; Maya Vetencourt, JF; O'Leary, OF; Sale, A; Viegi, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huttunen, HJ | 1 |
| Palva, JM | 1 |
| Lindberg, L | 1 |
| Palva, S | 1 |
| Saarela, V | 1 |
| Karvonen, E | 1 |
| Latvala, ML | 1 |
| Liinamaa, J | 1 |
| Booms, S | 1 |
| Castrén, E | 2 |
| Uusitalo, H | 1 |
| Sharif, MH | 1 |
| Talebnejad, MR | 1 |
| Rastegar, K | 1 |
| Khalili, MR | 1 |
| Nowroozzadeh, MH | 1 |
| Gore, C | 1 |
| Wu, C | 1 |
| Maya Vetencourt, JF | 1 |
| Sale, A | 1 |
| Viegi, A | 1 |
| Baroncelli, L | 1 |
| De Pasquale, R | 1 |
| O'Leary, OF | 1 |
| Maffei, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| FLOW Trial: Fluoxetine to Open the Critical Period Time Window to Improve Motor Recovery After Stroke[NCT03448159] | Phase 2 | 52 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluoxetine and Amblyopia
| Article | Year |
|---|---|
Medical Therapies of Amblyopia: Translational Research to Expand Our Treatment Armamentarium.
Topics: Amblyopia; Carbidopa; Cholinesterase Inhibitors; Donepezil; Dopamine Agonists; Drug Combinations; Fl | 2016 |
2 trials available for fluoxetine and Amblyopia
| Article | Year |
|---|---|
Fluoxetine does not enhance the effect of perceptual learning on visual function in adults with amblyopia.
Topics: Adult; Amblyopia; Female; Fluoxetine; Humans; Learning; Male; Middle Aged; Treatment Outcome; Vision | 2018 |
Oral fluoxetine in the management of amblyopic patients aged between 10 and 40 years old: a randomized clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Amblyopia; Child; Dose-Response Relationship, Drug; Double- | 2019 |
1 other study available for fluoxetine and Amblyopia
| Article | Year |
|---|---|
The antidepressant fluoxetine restores plasticity in the adult visual cortex.
Topics: Amblyopia; Animals; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Dia | 2008 |